8-K: Disc Medicine Announces Positive Phase 1b Trial Data for DISC-0974 in Chronic Kidney Disease Anemia

Disc Medicine reported positive results from a Phase 1b trial of DISC-0974, showing significant improvements in key markers for anemia in patients with non-dialysis-dependent chronic kidney disease.

Summary

• Disc Medicine announced positive data from its Phase 1b clinical trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia.
• The trial included single ascending doses (SAD) of 28 mg, 40 mg, and 60 mg of DISC-0974, compared to a placebo group.
• The data showed a substantial, dose-dependent reduction in hepcidin, with a median reduction greater than 75% from baseline at the highest dose level.
• There was a meaningful and sustained increase in transferrin saturation, with a median increase up to 3x from baseline at the highest dose level.
• The study also showed an early and sustained increase in mean reticulocyte hemoglobin across all dose groups.
• Mean hemoglobin increased from baseline across all dose groups, with a maximal mean increase of +0.8 g/dL at 40 mg and +0.7 g/dL at 60 mg compared to +0.2 g/dL on placebo.
• The maximal observed individual increase in hemoglobin was up to +1.8 g/dL at the 60 mg dose.
• DISC-0974 demonstrated acceptable safety and tolerability at all evaluated dose levels, with most adverse events not related to the treatment.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with clear improvements in key markers for anemia, suggesting a promising future for the drug. The safety profile is also acceptable, further boosting the positive sentiment.

Positives

• The study showed a clear dose-response relationship for DISC-0974.
• The drug demonstrated a substantial reduction in hepcidin, a key driver of anemia in CKD.
• The increase in transferrin saturation indicates improved iron availability for red blood cell production.
• The increase in hemoglobin levels suggests a potential therapeutic benefit for patients with CKD-related anemia.
• The safety profile of DISC-0974 was acceptable at all evaluated dose levels.

Negatives

• The study is still in Phase 1b, and further trials are needed to confirm these results.
• The data is from a single ascending dose study, and the long-term effects of the drug are not yet known.
• The study included a relatively small number of participants in each dose group.

Risks

• The clinical trial results may not be predictive of future results in larger studies.
• The company may face challenges in obtaining regulatory approval for DISC-0974.
• There are risks associated with the development and commercialization of new drugs.
• The company's ability to fund future operations and clinical trials is subject to market conditions and other factors.

Future Outlook

The company plans to explore dose regimens in the multiple-dose portion of the Phase 1b study and is looking to expand the use of DISC-0974 to address anemia caused by a range of inflammatory and chronic diseases.

Management Comments

• We are pleased to present these updated results, which provide the first clinical evidence in CKD anemia that reducing hepcidin through hemojuvelin translates into increased erythropoiesis and hemoglobin.
• Importantly, we were able to observe activity following only a single dose of DISC-0974, which will enable us to efficiently explore dose regimens in the multiple-dose portion of the phase 1b study.
• We have now shown that DISC-0974 can improve anemia in the settings of both myelofibrosis and chronic kidney disease. This speaks to the much broader potential for DISC-0974 to address anemia caused by a range of inflammatory and chronic diseases.

Industry Context

The results are significant as they address a major unmet need in the treatment of anemia associated with chronic kidney disease, a condition affecting millions worldwide. Current treatments have limitations, and DISC-0974's novel mechanism of action could offer a new approach.

Comparison to Industry Standards

• Current treatments for anemia in CKD often involve erythropoiesis-stimulating agents (ESAs) and iron supplementation, which can have limitations and safety concerns.
• The results of DISC-0974 show a different approach by targeting hepcidin, a key regulator of iron homeostasis, which could potentially offer a more effective and safer treatment option.
• Companies like Akebia Therapeutics and FibroGen have also been developing treatments for CKD anemia, but DISC-0974's mechanism of action is distinct, potentially offering a competitive advantage.
• The observed increase in hemoglobin levels and transferrin saturation are comparable to or better than some existing treatments, suggesting a promising profile for DISC-0974.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with CKD-related anemia may benefit from a new treatment option.
• The company's employees may be motivated by the positive progress of the drug development.

Next Steps

• The company will explore dose regimens in the multiple-dose portion of the Phase 1b study.
• The company plans to provide updates on its plans to access other indications for DISC-0974.

Key Dates

Keywords

DISC-0974, Chronic Kidney Disease, Anemia, Hepcidin, Transferrin Saturation, Hemoglobin, Phase 1b Trial, Hematologic Diseases, Erythropoiesis